# Editas Medicine, Inc. (EDIT)

> Source: Nexqual · https://nexqual.com/EDIT · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Editas Medicine, Inc. (EDIT), nexqual.com/EDIT" · informational, not investment advice.

**Price:** USD 2.95 (+13.46% on the day) · last close of Oct 28, 2026; US market closed, not a live price. Prev close 2.6 · day 2.54–2.96 · 52w 1.66–3.94 · market cap $453M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $47.0M, net income -$73.9M (-157.3% margin), free cash flow -$121M (SEC filings).
- Insider open-market sales, last ~7 months: 8 Form 4 filings, $79K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.62 on a 1–5 scale) (13 analysts), mean target USD 6.1 (range 1–15).
- Total return with dividends: 1Y -14.5% vs S&P 500 +13.2%; 5Y -92.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-09, EPS estimate USD -0.21, revenue estimate $4.5M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | $47.0M |
| Operating income | -$193M | -$226M | -$169M | -$251M | -$160M | -$75.9M |
| Net income | -$193M | -$220M | -$153M | -$237M | -$160M | -$73.9M |
| EPS (diluted) | -$2.85 | -$3.21 | -$2.02 | -$2.88 | -$1.80 | — |
| Free cash flow | -$172M | -$181M | -$137M | -$219M | -$166M | -$121M |
| Operating margin | -756.1% | -1146.3% | -216.6% | -777.2% | -394.9% | -161.4% |
| Net margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% | -157.3% |
| Revenue growth | -71.8% | -22.8% | +296.3% | -58.6% | +25.4% | — |
| Cash + short-term investments | $500M | $344M | $323M | $270M | $147M | — |
| Total debt | — | — | $0K | $57.4M | $58.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 9.6x · EV/Sales 6.3x · P/B 4.3x · FCF yield -26.61% · Earnings yield -16.32% · Net cash $156M · EV $297M

## Insider sales (SEC Form 4, open-market, last ~7 months)
8 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 709 | $2K | 1.1% | Yes (adopted July 3, 2023) | Too little history (no open-market trades in 2023) |
| 2026-09-03 | Parison Amy | SVP, Chief Financial Officer | 453 | $1K | 3.2% | Yes (adopted July 7, 2022) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-03 | O'Neill Gilmore Neil | CEO | 5,124 | $16K | 2.1% | Yes (adopted April 13, 2022) | Routine (sold in Jun each year 2023–2025; this trade is outside those months) |
| 2026-08-03 | Parison Amy | SVP, Chief Financial Officer | 678 | $2K | 4.5% | Yes (adopted July 7, 2022) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-28 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 4,928 | $13K | 7.3% | Yes (adopted July 3, 2023) | Too little history (no open-market trades in 2023) |
| 2026-06-03 | Parison Amy | SVP, Chief Financial Officer | 464 | $1K | 3% | Yes (adopted July 7, 2022) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-03 | O'Neill Gilmore Neil | CEO | 15,380 | $42K | 5.8% | Yes (adopted April 13, 2022) | Routine (sold in Jun each year 2023–2025) |
| 2026-06-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 731 | $2K | 1.1% | Yes (adopted July 3, 2023) | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.62 on a 1–5 scale), 13 analysts; mean target USD 6.1 (low 1, high 15).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | Wells Fargo | Upgrade | Equal-Weight → Overweight | $4 → $6 |
| 2026-09-23 | Guggenheim | Upgrade | Neutral → Buy | $5 |
| 2026-08-18 | Ladenburg Thalmann | Initiated | Buy | $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -14.5% | -92.0% |
| S&P 500 (SPY) | +13.2% | +79.8% |
| Per year | -14.6% | -39.5% |
| Volatility (annualized) | 80.9% | 77.8% |
| Max drawdown | -45.9% (Oct 2025→Feb 2026) | -97.3% (Nov 2021→Mar 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 91.97 -0.23% · ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · PRAX (Praxis Precision Medicines, Inc) USD 285.48 +6.69%

## More
Full page: https://nexqual.com/EDIT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in EDIT's own 10-K filed 2026-03-09 (https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/edit-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | The Broad Institute | "We are required to pay The Broad Institute, Inc. ("Broad") and the President and Fellows of Harvard College ("Harvard") a mid-double-digit percentage of amounts payable to us from Vertex under the Vertex License Agreemen…" |
| Partner | Vertex Pharmaceuticals | "In December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing tec…" |
| Partner | Beam Therapeutics Inc. (BEAM) | "Beam Therapeutics License Agreement" |
| Partner | Cowen and Company | "In May 2021, we entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) ("TD Cowen") under which we from time to time can issue and sell shares of our common stoc…" |

Other companies that name EDIT in their own reports (relationship from EDIT's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Beam Therapeutics Inc. (BEAM) | 10-K 2026-02-24 | "License agreement with Editas Medicine, Inc." |
| partner | VERTEX PHARMACEUTICALS INC / MA (VRTX) | 10-K 2026-02-13 | "2023, we entered into an agreement with Editas Medicine, Inc. ("Editas"), providing us a non-exclusive sublicense to certain" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.21 | $-0.27 | +$0.07 | $4.5M | 7 |
| Next quarter (ends 2026-12-31) | $-0.21 | $-0.25 | +$0.05 | $6.5M | 7 |
| Current fiscal year (ends 2026-12-31) | $-0.83 | $-0.99 | +$0.16 | $25.8M | 7 |
| Next fiscal year (ends 2027-12-31) | $-0.75 | $-0.91 | +$0.15 | $19.5M | 7 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-09): ±17.3%; last 8 reports averaged ±13%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 23 | 84.4% | ±17.3% |
| 2026-12-18 | 51 | 79.0% | ±24.0% |
| 2027-01-15 | 79 | 93.1% | ±34.6% |
| 2027-02-19 | 114 | 97.0% | ±41.3% |
| 2027-05-21 | 205 | 108.1% | ±59.6% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 5, 2026 | Quarter ended Jun 30, 2026 | −$0.15 | −$0.28 | Beat +46.4% | +4.7% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$0.26 | −$0.24 | Miss −8.3% | +5.8% |
| Mar 9, 2026 | Quarter ended Dec 31, 2025 | −$0.06 | −$0.21 | Beat +71.4% | +32.0% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$0.28 | −$0.38 | Beat +26.3% | +7.7% |
| Aug 12, 2025 | — | — | — | — | +40.0% |
| May 12, 2025 | — | — | — | — | +3.4% |
| Mar 5, 2025 | — | — | — | — | +1.1% |
| Jan 13, 2025 | — | — | — | — | -9.5% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-27 | Schedule 13G | BlackRock, Inc.: 7.8% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1650664/000201238326003773/0002012383-26-003773-index.htm |
| 2026-10-08 | 8-K | Regulation FD disclosure; Other material event — “On October 8, 2026, the Company announced that it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia. The trial has received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration and has also been submitted for review in New Zealand. If approved in New Zealand, patients in both countries will be eligible to enroll in the…” | https://www.sec.gov/Archives/edgar/data/1650664/000165066426000093/0001650664-26-000093-index.htm |
| 2026-08-14 | Schedule 13G | ADAR1 Capital Management, LLC, Daniel Schneeberger: 5.8% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1650664/000110465926097420/0001104659-26-097420-index.htm |
| 2026-08-05 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1650664/000165066426000083/0001650664-26-000083-index.htm |
| 2026-08-05 | 8-K | Quarterly results; Director or executive officer change, or pay arrangement — “On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the "Board") of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026. The resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On August 4, 2026, the Board, upon recommendation of the Board's Nominating and Corporate Governance Committee, appointed Patrick Ellinor, M.D., Ph.D. as an independent director,…” | https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/0001650664-26-000082-index.htm |
| 2026-07-29 | Schedule 13G/A | BlackRock, Inc.: 5.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1650664/000201238326002798/0002012383-26-002798-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.